form8_k060809.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported) June 8, 2009
Progenics
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-23143
|
|
13-3379479
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
|
777
Old Saw Mill River Road, Tarrytown, New York
|
|
10591
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant's
telephone number, including area code (914)
789-2800
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other Events.
On June
8, 2009, Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that its
collaborator, Ono Pharmaceutical Co., Ltd., Osaka, Japan (OSE-TYO: 4528), has
begun clinical testing in Japan of RELISTOR®
(methylnaltrexone bromide) subcutaneous injection pursuant to the License
Agreement between Progenics and Ono, under which Ono has exclusive rights to
subcutaneous RELISTOR in Japan and where it is pursuing plans to develop and
commercialize the drug, designated ONO-3849, for the treatment of opioid-induced
constipation.
On the
same date, Progenics announced the discontinuation of development for PRO 206, a
pre-clinical compound for the treatment of hepatitis C virus (HCV) infection, in
line with its ongoing initiative to allocate resources to the most important
programs in order to increase operating efficiencies, and that it will instead
focus on its second-generation HCV-entry inhibitor portfolio, anticipating
selection of a new development candidate in 2010.
Copies of
each press release are attached hereto as Exhibits 99.1 and 99.2, respectively,
and the information contained therein is incorporated by reference into this
Item 8.01 of this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No. Description
|
99.1
|
Relistor
Press Release dated June 8, 2009.
|
|
99.2
|
PRO
206 Press Release dated June 8,
2009.
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
PROGENICS
PHARMACEUTICALS, INC.
By: /s/ ROBERT A.
MCKINNEY
Robert A.
McKinney
Chief Financial
Officer, Senior Vice President,
Finance &
Operations and Treasurer
Date: June
8, 2009